KC1036

· Beijing Konruns Pharmaceutical Co., Ltd.

Drug timelines are a Plus or Pro feature.

6 regulatory and trial events tracked for KC1036, covering 2024-03-07 to 2026-03-20. Get the full timeline:

Most recent: Clinical Trial Update: KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer [Phase 2]

See pricing